Menu
  • CAP 256 team visits VRC

    Professor Lynn Morris, CAPRISA Research Associate and head of the HIV Virology section in the Center for HIV and STIs at the National Institutes of Communicable Diseases in South Africa recently visited the NIH Vaccine Research Center’s (VRC) Gaithersburg process plant as well as the Frederick pilot plant where the manufacture of the CAP256-VRC26.25 antibody for human clinical trials is underway. Prof Morris gave a research seminar at the VRC where she discussed the history of the CAP256 donor and various studies on the isolated antibodies as well as the plans for the upcoming clinical trials.

     

    Share this article

    Back

Centre for the AIDS Programme of Research in South Africa

CAPRISA was created in 2001 and formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care.